Aims and Scope
Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original research. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.
Why Publish in Cancer Drug Resistance
1. Open access to all published articles.
2. No charge for manuscript processing, publication, and reproduction.
3. Rapid publication for high-quality manuscripts: 45 days at most.
4. Rigorous peer review.
5. Accessible to a global readership.
6. Promotion of published articles in various channels worldwide.
Open Access Statement
Cancer Drug Resistance
is committed to open access for academic work. All of Cancer Drug Resistance’s
articles are free for immediate access from the date of publication. There is no charge for manuscripts’ processing and publication and there is no charge for readers to read, subscribe, copy, print, and download.Cancer Drug Resistance
also operates under Creative Commons Attribution 4.0 International License
which allows others to remix, tweak and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.